These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8571)

  • 1. Participation of cyclophosphamide-sensitive T cells in graft-vs-host reactions.
    Schwartz A; Orbach-Arbouys S; Gershon RK
    J Immunol; 1976 Sep; 117(3):871-5. PubMed ID: 8571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation and suppression of graft-vs-host reactions by cyclophosphamide.
    Wander RH; Hilgard HR
    J Immunol; 1981 Mar; 126(3):901-4. PubMed ID: 7462635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vitro.
    Shand FL
    Immunology; 1978 Dec; 35(6):1017-25. PubMed ID: 33118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of cyclophosphamide on antibody formation in the mouse.
    Willers JM; Sluis E
    Ann Immunol (Paris); 1975 Apr; 126(3):267-79. PubMed ID: 1101799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Participation of mouse T- and B-lymphocytes in the graft versus host reaction].
    Bliakher MS
    Biull Eksp Biol Med; 1976 Jun; 81(6):713-5. PubMed ID: 8176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subpopulations of mouse T lymphocytes. II. Suppression of graft-vs.-host reactions by naturally proliferating splenic T cells.
    Moorhead JW
    Eur J Immunol; 1978 Mar; 8(3):163-7. PubMed ID: 26575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration.
    Lehnert S; Rybka WB
    Bone Marrow Transplant; 1994 Apr; 13(4):473-7. PubMed ID: 8019473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of delayed-type hypersensitivity reactions by cyclophosphamide-sensitive T cells.
    Schwartz A; Askenase PW; Gershon RK
    J Immunol; 1978 Oct; 121(4):1573-7. PubMed ID: 308970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interferonogenic agent tilorone as a modulator of GvH reaction in mice.
    Zschiesche W; Slavina E; Leipunskaya I
    Arch Immunol Ther Exp (Warsz); 1977; 25(5):725-30. PubMed ID: 23088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue distribution of I region-associated antigens in the mouse.
    Hauptfeld V; Hauptfeld M; Klein J
    J Immunol; 1974 Jul; 113(1):181-8. PubMed ID: 4598886
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of proline-rich polypeptide on donor cells in graft-versus-host reaction.
    Zimecki M; Janusz M; Starościk K; Lisowski J; Wieczorek Z
    Immunology; 1982 Sep; 47(1):141-7. PubMed ID: 6981586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune competence of splenic lymphocytes following graft-vs-host disease in mouse allogeneic radiation chimeras.
    Urso P; Gengozian N
    J Immunol; 1977 Feb; 118(2):657-61. PubMed ID: 14214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syngeneic GvH induced in popliteal lymph nodes by spleen cells of old C57BL/6 mice.
    Gozes Y; Umiel T; Meshorer A; Trainin N
    J Immunol; 1978 Dec; 121(6):2199-204. PubMed ID: 31401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice.
    Eto M; Mayumi H; Tomita Y; Yoshikai Y; Nishimura Y; Maeda T; Ando T; Nomoto K
    J Immunol; 1991 Mar; 146(5):1402-9. PubMed ID: 1671578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction. Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations.
    Ghayur T; Seemayer TA; Lapp WS
    Transplantation; 1987 Aug; 44(2):254-60. PubMed ID: 3498241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of immunosuppression generated by the graft-versus-host reaction. II. Characterization of the suppression cell and its mechanism of action.
    Shand FL
    Immunology; 1976 Dec; 31(6):943-51. PubMed ID: 11181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleolar and functional characterization of lymphocytes following cyclophosphamide treatment.
    Dráber P; Nouza K
    Folia Biol (Praha); 1977; 23(3):158-69. PubMed ID: 18371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tilorone hydrochloride on graft-versus-host (GvH) reaction in mice.
    Zschiesche W; Slavina E; Leipunskaya I
    Acta Biol Med Ger; 1977; 36(1):107-12. PubMed ID: 17988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.